^
Association details:
| Biomarker: | MSI-H/dMMR + KMT2D mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Puyouheng (pucotenlimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
Published date:
11/15/2023
Excerpt:
Overall, 100 patients with previously treated, advanced solid tumors centrally confirmed as dMMR or MSI-H received pucotenlimab at 200 mg every 3 weeks. The most common cancer type is colorectal cancer (n = 71)...For the biomarker analysis, responders are enriched in patients with mutations in the KMT2D gene. Pucotenlimab is an effective treatment option for previously treated advanced dMMR/MSI-H solid tumors...
DOI:
10.1016/j.xcrm.2023.101301
Trial ID:
Source:
Title:
Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study.
Published date:
01/17/2023
Excerpt:
The ORR was 49.0% (95% CI 38.86%-59.20%), and the 12-month progression-free survival (PFS) rate was 56.1% (95% CI 45.63%-65.24%) based on IRC’s assessment…. For the biomarker analysis, patients with NLR <4 at the second treatment cycle, TMB≥32.5 muts/Mb (the lower 35th TMB-percentile), or mutations in the KMT2D gene showed significantly higher ORR....Pucotenlimab demonstrated durable antitumor activity and manageable safety for previously treated patients with advanced MSI-H/dMMR solid tumors.
DOI:
10.1200/JCO.2023.41.3_suppl.799
Trial ID:
